SPP1 and neoplasm: Furthermore, the combination of anti-OPN monoclonal antibodies and anti-PD1 is more efficient in reducing tumors nodules than anti-PD1 immunotherapy alone [132].These data suggest that OPN can compensate for PD-L1 to promote immune escape of the tumor, thereby rendering the tumor cells resistant to immunotherapy.